{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:49:23Z","timestamp":1782132563117,"version":"3.54.5"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05423-5","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T13:34:35Z","timestamp":1755610475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of Plasmodium falciparum plasmepsin2\/3 gene duplication in Africa and Asia: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Karol J.","family":"Marwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manase","family":"Kilonzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajabu Hussein","family":"Mnkugwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Baraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Kapesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mwaiswelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno P.","family":"Mmbando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P. A.","family":"Lusingu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmus","family":"Kamugisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"5423_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s13071-017-2298-y","volume":"10","author":"F Lu","year":"2017","unstructured":"Lu F, Zhang M, Culleton RL, Xu S, Tang J, Zhou H, et al. Return of chloroquine sensitivity to Africa? Surveillance of African Plasmodium falciparum chloroquine resistance through malaria imported to China. Parasit Vectors. 2017;10:355.","journal-title":"Parasit Vectors"},{"key":"5423_CR2","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1017\/S0950268820003167","volume":"149","author":"G Kishoyian","year":"2021","unstructured":"Kishoyian G, Njagi EN, Orinda GO, Kimani FT, Thiongo K, Matoke-Muhia D. Efficacy of artemisinin\u2013lumefantrine for treatment of uncomplicated malaria after more than a decade of its use in Kenya. Epidemiol Infect. 2021;149:e27.","journal-title":"Epidemiol Infect"},{"key":"5423_CR3","volume-title":"Guidelines for malaria 2023","author":"WHO","year":"2023","unstructured":"WHO. Guidelines for malaria 2023. Geneva: World Health Organization; 2023."},{"key":"5423_CR4","volume-title":"Global technical strategy for malaria 2016\u20132030","author":"WHO","year":"2015","unstructured":"WHO. Global technical strategy for malaria 2016\u20132030. Geneva: World Health Organization; 2015."},{"key":"5423_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1056\/NEJMc0900231","volume":"361","author":"H Noedl","year":"2009","unstructured":"Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. New Engl J Med. 2009;361:540\u20131.","journal-title":"New Engl J Med"},{"key":"5423_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"5423_CR7","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1473-3099(24)00362-1","volume":"24","author":"DS Ishengoma","year":"2024","unstructured":"Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, et al. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect Dis. 2024;24:1225\u201333.","journal-title":"Lancet Infect Dis"},{"key":"5423_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Eng J Med. 2021;385:1163\u201371.","journal-title":"N Eng J Med"},{"key":"5423_CR9","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana J-LM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"5423_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijpddr.2021.06.001","volume":"16","author":"L Ndwiga","year":"2021","unstructured":"Ndwiga L, Kimenyi KM, Wamae K, Osoti V, Akinyi M, Omedo I, Ishengoma DS, et al. A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa. Int J Parasitol Drugs Drug Resist. 2021;16:155\u201361.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5423_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijpddr.2019.10.001","volume":"11","author":"J Chhibber-Goel","year":"2019","unstructured":"Chhibber-Goel J, Sharma A. Profiles of Kelch mutations in Plasmodium falciparum across South Asia and their implications for tracking drug resistance. Int J Parasitol Drugs Drug Resist. 2019;11:49\u201358.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5423_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s12936-021-03987-6","volume":"20","author":"A Owoloye","year":"2021","unstructured":"Owoloye A, Olufemi M, Idowu ET, Oyebola KM. Prevalence of potential mediators of artemisinin resistance in African isolates of Plasmodium falciparum. Malar J. 2021;20:451.","journal-title":"Malar J"},{"key":"5423_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijpddr.2020.11.006","volume":"15","author":"A Arya","year":"2021","unstructured":"Arya A, Foko LPK, Chaudhry S, Sharma A, Singh V. Artemisinin-based combination therapy (ACT) and drug resistance molecular markers: a systematic review of clinical studies from two malaria endemic regions\u2013India and sub-Saharan Africa. Int J Parasitol Drugs Drug Resist. 2021;15:43\u201356.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5423_CR14","doi-asserted-by":"publisher","first-page":"101919","DOI":"10.1016\/j.parint.2019.04.016","volume":"74","author":"PG Mathenge","year":"2020","unstructured":"Mathenge PG, Low SK, Vuong NL, Mohamed MYF, Faraj HA, Alieldin GI, et al. Efficacy and resistance of different artemisinin-based combination therapies: a systematic review and network meta-analysis. Parasitol Int. 2020;74:101919.","journal-title":"Parasitol Int"},{"key":"5423_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00436-024-08301-2","volume":"123","author":"CS Milong Melong","year":"2024","unstructured":"Milong Melong CS, Peloewetse E, Russo G, Tamgue O, Tchoumbougnang F, Paganotti GM. An overview of artemisinin-resistant malaria and associated Pfk13 gene mutations in Central Africa. Parasitol Res. 2024;123:277.","journal-title":"Parasitol Res"},{"key":"5423_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/tropicalmed4010026","volume":"4","author":"C Nsanzabana","year":"2019","unstructured":"Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.","journal-title":"Trop Med Infect Dis"},{"key":"5423_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1475-2875-8-253","volume":"8","author":"NJ White","year":"2009","unstructured":"White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J. 2009;8:253.","journal-title":"Malar J"},{"key":"5423_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/bcp.14474","volume":"88","author":"B Hanboonkunupakarn","year":"2022","unstructured":"Hanboonkunupakarn B, White NJ. Advances and roadblocks in the treatment of malaria. Br J Clin Pharmacol. 2022;88:374\u201382.","journal-title":"Br J Clin Pharmacol"},{"key":"5423_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pt.2020.09.011","volume":"37","author":"RW van der Pluijm","year":"2021","unstructured":"van der Pluijm RW, Amaratunga C, Dhorda M, Dondorp AM. Triple artemisinin-based combination therapies for malaria\u2013a new paradigm? Trends Parasitol. 2021;37:15\u201324.","journal-title":"Trends Parasitol"},{"key":"5423_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1473-3099(22)00822-2","volume":"23","author":"T Burki","year":"2023","unstructured":"Burki T. WHO antimalarial strategy for Africa. Lancet Infect Dis. 2023;23:37\u20138.","journal-title":"Lancet Infect Dis"},{"key":"5423_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12936-017-1680-8","volume":"16","author":"NV Thanh","year":"2017","unstructured":"Thanh NV, Thuy-Nhien N, Tuyen NTK, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin\u2013piperaquine in the south of Vietnam. Malar J. 2017;16:27.","journal-title":"Malar J"},{"key":"5423_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12936-022-04181-y","volume":"21","author":"S Moss","year":"2022","unstructured":"Moss S, Ma\u0144ko E, Krishna S, Campino S, Clark TG, Last A, et al. How has mass drug administration with dihydroartemisinin-piperaquine impacted molecular markers of drug resistance? A systematic review. Malar J. 2022;21:186.","journal-title":"Malar J"},{"key":"5423_CR23","volume-title":"World malaria report 2023","author":"WHO","year":"2023","unstructured":"WHO. World malaria report 2023. Geneva: World Health Organization; 2023."},{"key":"5423_CR24","volume-title":"Malaria: biology in the era of eradication","author":"D Wirth","year":"2017","unstructured":"Wirth D, Alonso P. Malaria: biology in the era of eradication. New York: Cold Spring Harbour Laboratory Press; 2017."},{"key":"5423_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-micro-020518-115546","volume":"74","author":"KJ Wicht","year":"2020","unstructured":"Wicht KJ, Mok S, Fidock DA. Molecular mechanisms of drug resistance in Plasmodium falciparum malaria. Annu Rev Microbiol. 2020;74:431\u201354.","journal-title":"Annu Rev Microbiol"},{"key":"5423_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","volume":"17","author":"B Witkowski","year":"2017","unstructured":"Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype\u2013genotype association study. Lancet Infect Dis. 2017;17:174\u201383.","journal-title":"Lancet Infect Dis"},{"key":"5423_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12916-015-0539-5","volume":"13","author":"V Duru","year":"2015","unstructured":"Duru V, Khim N, Leang R, Kim S, Domergue A, Kloeung N, et al. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Med. 2015;13:305.","journal-title":"BMC Med"},{"key":"5423_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","volume":"17","author":"R Amato","year":"2017","unstructured":"Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin\u2013piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype\u2013phenotype association study. Lancet Infect Dis. 2017;17:164\u201373.","journal-title":"Lancet Infect Dis"},{"key":"5423_CR29","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19:952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"5423_CR30","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.1074\/jbc.REV120.009309","volume":"295","author":"AS Nasamu","year":"2020","unstructured":"Nasamu AS, Polino AJ, Istvan ES, Goldberg DE. Malaria parasite plasmepsins: more than just plain old degradative pepsins. J Biol Chem. 2020;295:8425\u201341.","journal-title":"J Biol Chem"},{"key":"5423_CR31","doi-asserted-by":"crossref","unstructured":"Ndiaye YD, Wong W, Thwing J, Schaffner SS, Tine A, Diallo MA, et al. Two decades of molecular surveillance in Senegal reveal changes in known drug resistance mutations associated with historical drug use and seasonal malaria chemoprevention. medRxiv. (preprint). 2023.","DOI":"10.1101\/2023.04.24.23288820"},{"key":"5423_CR32","first-page":"1","volume":"14","author":"A Gaye","year":"2022","unstructured":"Gaye A, Ndiaye T, Sy M, Deme AB, Dieye B, Ndiaye YD, et al. Surveillance of plasmepsin 2 copy number gene in Plasmodium falciparum isolates from Senegal. J Parasitol Vector Biol. 2022;14:1\u20137.","journal-title":"J Parasitol Vector Biol"},{"key":"5423_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"5423_CR34","volume-title":"Study quality assessment tools","author":"National Heart Lung, and Blood Institute","year":"2018","unstructured":"National Heart Lung, and Blood Institute. Study quality assessment tools. Bethesda: National Institutes of Health; 2018."},{"key":"5423_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"5423_CR36","doi-asserted-by":"publisher","first-page":"f4040","DOI":"10.1136\/bmj.f4040","volume":"346","author":"P Sedgwick","year":"2013","unstructured":"Sedgwick P. Meta-analyses: heterogeneity and subgroup analysis. BMJ. 2013;346:f4040.","journal-title":"BMJ"},{"key":"5423_CR37","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"key":"5423_CR38","volume-title":"Strategy to respond to antimalarial drug resistance in Africa. In Strategy to respond to antimalarial drug resistance in Africa","author":"WHO","year":"2022","unstructured":"WHO. Strategy to respond to antimalarial drug resistance in Africa. In Strategy to respond to antimalarial drug resistance in Africa. Geneva: World Health Organization; 2022."},{"key":"5423_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/01.qco.0000186848.46417.6c","volume":"18","author":"EA Ashley","year":"2005","unstructured":"Ashley EA, White NJ. Artemisinin-based combinations. Curr Opin Infect Dis. 2005;18:531\u20136.","journal-title":"Curr Opin Infect Dis"},{"key":"5423_CR40","volume-title":"World malaria report 2020: 20 years of global progress and challenges","author":"WHO","year":"2020","unstructured":"WHO. World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization; 2020."},{"key":"5423_CR41","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3201\/eid2408.180370","volume":"24","author":"J Inoue","year":"2018","unstructured":"Inoue J, Silva M, Fofana B, Sanogo K, M\u00e5rtensson A, Sagara I, et al. Plasmodium falciparum plasmepsin 2 duplications, West Africa. Emerg Infect Dis. 2018;24:1591.","journal-title":"Emerg Infect Dis"},{"key":"5423_CR42","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12936-016-1569-y","volume":"15","author":"S Chaorattanakawee","year":"2016","unstructured":"Chaorattanakawee S, Lon C, Jongsakul K, Gawee J, Sok S, Sundrakes S, et al. Ex vivo piperaquine resistance developed rapidly in Plasmodium falciparum isolates in northern Cambodia compared to Thailand. Malar J. 2016;15:519.","journal-title":"Malar J"},{"key":"5423_CR43","doi-asserted-by":"crossref","unstructured":"Li M, Liu H, Tang L, Yang H, Bustos MDG, Tu H, et al. Genetic features of P. falciparum parasites collected in 2012\u20132016 and anti-malaria resistance along China-Myanmar border. Research Square. (preprint). 2020.","DOI":"10.21203\/rs.3.rs-81492\/v1"},{"key":"5423_CR44","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/ph14040351","volume":"14","author":"M Gendrot","year":"2021","unstructured":"Gendrot M, Delandre O, Robert MG, Foguim FT, Benoit N, Amalvict R, et al. Absence of association between methylene blue reduced susceptibility and polymorphisms in 12 genes involved in antimalarial drug resistance in African Plasmodium falciparum. Pharmaceuticals (Basel). 2021;14:351.","journal-title":"Pharmaceuticals (Basel)"},{"key":"5423_CR45","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12936-020-03410-6","volume":"19","author":"F Huang","year":"2020","unstructured":"Huang F, Shrestha B, Liu H, Tang L-H, Zhou S-S, Zhou X-N, et al. No evidence of amplified Plasmodium falciparum plasmepsin II gene copy number in an area with artemisinin-resistant malaria along the China-Myanmar border. Malar J. 2020;19:334.","journal-title":"Malar J"},{"key":"5423_CR46","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/cid\/ciaa628","volume":"73","author":"M Mairet-Khedim","year":"2021","unstructured":"Mairet-Khedim M, Leang R, Marmai C, Khim N, Kim S, Ke S, et al. Clinical and in vitro resistance of Plasmodium falciparum to artesunate-amodiaquine in Cambodia. Clin Infect Dis. 2021;73:406\u201313.","journal-title":"Clin Infect Dis"},{"key":"5423_CR47","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1093\/jac\/dkab281","volume":"76","author":"M Mairet-Khedim","year":"2021","unstructured":"Mairet-Khedim M, Nsango S, Ngou C, Menard S, Roesch C, Khim N, et al. Efficacy of dihydroartemisinin\/piperaquine in patients with non-complicated Plasmodium falciparum malaria in Yaound\u00e9, Cameroon. J Antimicrob Chemother. 2021;76:3037\u201344.","journal-title":"J Antimicrob Chemother"},{"key":"5423_CR48","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1128\/AAC.00835-15","volume":"59","author":"R Leang","year":"2015","unstructured":"Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"5423_CR49","doi-asserted-by":"publisher","first-page":"e01516","DOI":"10.1128\/AAC.01516-17","volume":"61","author":"SA Rasmussen","year":"2017","unstructured":"Rasmussen SA, Ceja FG, Conrad MD, Tumwebaze PK, Byaruhanga O, Katairo T, et al. Changing antimalarial drug sensitivities in Uganda. Antimicrob Agents Chemother. 2017;61:e01516-e1517.","journal-title":"Antimicrob Agents Chemother"},{"key":"5423_CR50","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/bfgp\/elz008","volume":"18","author":"AN Cowell","year":"2019","unstructured":"Cowell AN, Winzeler EA. The genomic architecture of antimalarial drug resistance. Brief Funct Genomics. 2019;18:314\u201328.","journal-title":"Brief Funct Genomics"},{"key":"5423_CR51","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12936-020-03339-w","volume":"19","author":"N Boonyalai","year":"2020","unstructured":"Boonyalai N, Vesely BA, Thamnurak C, Praditpol C, Fagnark W, Kirativanich K, et al. Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization. Malar J. 2020;19:269.","journal-title":"Malar J"},{"key":"5423_CR52","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12936-021-03711-4","volume":"20","author":"DG Assefa","year":"2021","unstructured":"Assefa DG, Zeleke ED, Bekele D, Tesfahunei HA, Getachew E, Joseph M, et al. Efficacy and safety of dihydroartemisinin\u2013piperaquine versus artemether\u2013lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials. Malar J. 2021;20:174.","journal-title":"Malar J"},{"key":"5423_CR53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12936-016-1099-7","volume":"15","author":"A Adjei","year":"2016","unstructured":"Adjei A, Narh-Bana S, Amu A, Kukula V, Nagai RA, Owusu-Agyei S, et al. Treatment outcomes in a safety observational study of dihydroartemisinin\/piperaquine (Eurartesim\u00ae) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malar J. 2016;15:43.","journal-title":"Malar J"},{"key":"5423_CR54","doi-asserted-by":"publisher","first-page":"e0240174","DOI":"10.1371\/journal.pone.0240174","volume":"15","author":"H Gupta","year":"2020","unstructured":"Gupta H, Galatas B, Chidimatembue A, Huijben S, Cister\u00f3 P, Matambisso G, et al. Effect of mass dihydroartemisinin\u2013piperaquine administration in southern Mozambique on the carriage of molecular markers of antimalarial resistance. PLoS ONE. 2020;15:e0240174.","journal-title":"PLoS ONE"},{"key":"5423_CR55","doi-asserted-by":"publisher","first-page":"e0264339","DOI":"10.1371\/journal.pone.0264339","volume":"17","author":"K Marwa","year":"2022","unstructured":"Marwa K, Kapesa A, Baraka V, Konje E, Kidenya B, Mukonzo J, et al. Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2022;17:e0264339.","journal-title":"PLoS ONE"},{"key":"5423_CR56","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1016\/S1473-3099(24)00141-5","volume":"24","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect Dis. 2024;24:e591\u2013600.","journal-title":"Lancet Infect Dis"},{"key":"5423_CR57","doi-asserted-by":"publisher","first-page":"taaa231","DOI":"10.1093\/jtm\/taaa231","volume":"28","author":"M L'Episcopia","year":"2021","unstructured":"L\u2019Episcopia M, Bartoli TA, Corpolongo A, Mariano A, D\u2019Abramo A, Vulcano A, et al. Artemisinin resistance surveillance in African Plasmodium falciparum isolates from imported malaria cases to Italy. J Travel Med. 2021;28:taaa231.","journal-title":"J Travel Med"},{"key":"5423_CR58","first-page":"e00413","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, Liang X, Li J, Chen J, Huang H, Zheng Y, et al. Molecular surveillance of artemisinin-based combination therapies resistance in Plasmodium falciparum parasites from Bioko Island, Equatorial Guinea. Microbiol Spectr. 2022;10:e00413-e422.","journal-title":"Microbiol Spectr"},{"key":"5423_CR59","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12936-018-2524-x","volume":"17","author":"MA Kakolwa","year":"2018","unstructured":"Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malar J. 2018;17:369.","journal-title":"Malar J"},{"key":"5423_CR60","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12936-019-2756-4","volume":"18","author":"D Leroy","year":"2019","unstructured":"Leroy D, Macintyre F, Adoke Y, Ouoba S, Barry A, Mombo-Ngoma G, et al. African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker. Malar J. 2019;18:126.","journal-title":"Malar J"},{"key":"5423_CR61","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12936-022-04382-5","volume":"21","author":"KN Win","year":"2022","unstructured":"Win KN, Manopwisedjaroen K, Phumchuea K, Suansomjit C, Chotivanich K, Lawpoolsri S, et al. Molecular markers of dihydroartemisinin-piperaquine resistance in northwestern Thailand. Malar J. 2022;21:352.","journal-title":"Malar J"},{"key":"5423_CR62","doi-asserted-by":"crossref","unstructured":"Diarra H, Mobegi VA, Makhulu EE, Kinyua J, Herren JK. Absolute quantification of gene copy number variation in Plasmodium falciparum novel putative genes associated to drug resistance (the actin-binding coronin protein, cysteine desulfurase and plasmepsin 2), using Eva green-based quantitative PCR. Research Square. (preprint). 2022.","DOI":"10.21203\/rs.3.rs-1451928\/v1"},{"key":"5423_CR63","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12936-022-04140-7","volume":"21","author":"VS Koko","year":"2022","unstructured":"Koko VS, Warsame M, Vonhm B, Jeuronlon MK, Menard D, Ma L, et al. Artesunate\u2013amodiaquine and artemether\u2013lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers. Malar J. 2022;21:134.","journal-title":"Malar J"},{"key":"5423_CR64","doi-asserted-by":"publisher","first-page":"e01818","DOI":"10.1128\/AAC.01818-18","volume":"63","author":"V Asua","year":"2019","unstructured":"Asua V, Vinden J, Conrad MD, Legac J, Kigozi SP, Kamya MR, et al. Changing molecular markers of antimalarial drug sensitivity across Uganda. Antimicrob Agents Chemother. 2019;63:e01818.","journal-title":"Antimicrob Agents Chemother"},{"key":"5423_CR65","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/cid\/ciz580","volume":"70","author":"P Quang Bui","year":"2020","unstructured":"Quang Bui P, Hong Huynh Q, Thanh Tran D, Le Thanh D, Quang Nguyen T, Van Truong H, et al. Pyronaridine-artesunate efficacy and safety in uncomplicated Plasmodium falciparum malaria in areas of artemisinin-resistant falciparum in Viet Nam (2017\u20132018). Clin Infect Dis. 2020;70:2187\u201395.","journal-title":"Clin Infect Dis"},{"key":"5423_CR66","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(18)30792-X","volume":"391","author":"J Landier","year":"2018","unstructured":"Landier J, Parker DM, Thu AM, Lwin KM, Delmas G, Nosten FH, et al. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet. 2018;391:1916\u201326.","journal-title":"Lancet"},{"key":"5423_CR67","doi-asserted-by":"publisher","first-page":"e00276","DOI":"10.1128\/AAC.00276-21","volume":"65","author":"ND Manh","year":"2021","unstructured":"Manh ND, Thanh NV, Quang HH, Van NTT, San NN, Phong NC, et al. Pyronaridine-artesunate (Pyramax) for treatment of artemisinin-and piperaquine-resistant Plasmodium falciparum in the central highlands of Vietnam. Antimicrob Agents Chemother. 2021;65:e00276-e321.","journal-title":"Antimicrob Agents Chemother"},{"key":"5423_CR68","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20:48.","journal-title":"Malar J"},{"key":"5423_CR69","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/infdis\/jix334","volume":"216","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Moser KA, Morton L, Cummings MP, Parihar A, Dwivedi A, et al. Association of a novel mutation in the Plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity. J Infect Dis. 2017;216:468\u201376.","journal-title":"J Infect Dis"},{"key":"5423_CR70","first-page":"387","volume":"3","author":"NO Duah-Quashie","year":"2022","unstructured":"Duah-Quashie NO, Agyarkwah MA, Hodoameda P, Bruku S, Abuaku B, Koram K, et al. Copy number variation of plasmepsins 2 and 3 genes in Plasmodium falciparum isolates and implication for dihydroartemisinin-piperaquine resistance in Ghana. Health Sci Investig J. 2022;3:387\u201392.","journal-title":"Health Sci Investig J"},{"key":"5423_CR71","first-page":"2272","volume":"75","author":"E Rovira-Vallbona","year":"2020","unstructured":"Rovira-Vallbona E, Van Hong N, Kattenberg JH, Huan RM, Hien NTT, Ngoc NTH, et al. Efficacy of dihydroartemisinin\/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam. J Antimicrob Chemother. 2020;75:2272\u201381.","journal-title":"J Antimicrob Chemother"},{"key":"5423_CR72","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12936-017-2091-6","volume":"16","author":"DH Son","year":"2017","unstructured":"Son DH, Thuy-Nhien N, von Seidlein L, Le Phuc-Nhi T, Phu NT, Tuyen NTK, et al. The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc province, Vietnam: a pilot study. Malar J. 2017;16:444.","journal-title":"Malar J"},{"key":"5423_CR73","first-page":"e02242","volume":"63","author":"R Leang","year":"2019","unstructured":"Leang R, Mairet-Khedim M, Chea H, Huy R, Khim N, Mey Bouth D, et al. Efficacy and Safety of pyronaridine-artesunate plus single-dose primaquine for treatment of uncomplicated Plasmodium falciparum malaria in eastern Cambodia. Antimicrob Agents Chemother. 2019;63:e02242-e2318.","journal-title":"Antimicrob Agents Chemother"},{"key":"5423_CR74","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/infdis\/jix421","volume":"216","author":"MD Conrad","year":"2017","unstructured":"Conrad MD, Mota D, Foster M, Tukwasibwe S, Legac J, Tumwebaze P, et al. Impact of intermittent preventive treatment during pregnancy on Plasmodium falciparum drug resistance\u2013mediating polymorphisms in Uganda. J Infect Dis. 2017;216:1008\u201317.","journal-title":"J Infect Dis"},{"key":"5423_CR75","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12936-019-2640-2","volume":"18","author":"NC Phong","year":"2019","unstructured":"Phong NC, Chavchich M, Quang HH, San NN, Birrell GW, Chuang I, et al. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam. Malar J. 2019;18:10.","journal-title":"Malar J"},{"key":"5423_CR76","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12936-021-04021-5","volume":"20","author":"C Ebong","year":"2021","unstructured":"Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J. 2021;20:484.","journal-title":"Malar J"},{"key":"5423_CR77","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12936-020-03358-7","volume":"19","author":"W Chebore","year":"2020","unstructured":"Chebore W, Zhou Z, Westercamp N, Otieno K, Shi YP, Sergent SB, et al. Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya. Malar J. 2020;19:291.","journal-title":"Malar J"},{"key":"5423_CR78","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13071-022-05239-1","volume":"15","author":"R Ye","year":"2022","unstructured":"Ye R, Zhang Y, Zhang D. Evaluations of candidate markers of dihydroartemisinin-piperaquine resistance in Plasmodium falciparum isolates from the China-Myanmar, Thailand-Myanmar, and Thailand-Cambodia borders. Parasit Vectors. 2022;15:130.","journal-title":"Parasit Vectors"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05423-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05423-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05423-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:47:47Z","timestamp":1757411267000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05423-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5423"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05423-5","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable because it is a systematic review and metanalysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for a systematic review and meta-analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}